Pulse Biosciences (NASDAQ: PLSE) is one of 79 public companies in the “Advanced Medical Equipment & Technology” industry, but how does it weigh in compared to its rivals? We will compare Pulse Biosciences to related companies based on the strength of its earnings, dividends, institutional ownership, valuation, profitability, risk and analyst recommendations.
This table compares Pulse Biosciences and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Pulse Biosciences Competitors||-153.84%||-22.96%||-9.32%|
Pulse Biosciences has a beta of 2.4, suggesting that its stock price is 140% more volatile than the S&P 500. Comparatively, Pulse Biosciences’ rivals have a beta of 1.21, suggesting that their average stock price is 21% more volatile than the S&P 500.
Insider & Institutional Ownership
9.3% of Pulse Biosciences shares are held by institutional investors. Comparatively, 51.9% of shares of all “Advanced Medical Equipment & Technology” companies are held by institutional investors. 6.7% of Pulse Biosciences shares are held by insiders. Comparatively, 18.4% of shares of all “Advanced Medical Equipment & Technology” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
This is a summary of recent ratings for Pulse Biosciences and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Pulse Biosciences Competitors||337||1996||3511||112||2.57|
As a group, “Advanced Medical Equipment & Technology” companies have a potential downside of 3.33%. Given Pulse Biosciences’ rivals higher probable upside, analysts plainly believe Pulse Biosciences has less favorable growth aspects than its rivals.
Valuation and Earnings
This table compares Pulse Biosciences and its rivals top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Pulse Biosciences||N/A||-$9.51 million||-15.38|
|Pulse Biosciences Competitors||$2.15 billion||$223.68 million||-83.81|
Pulse Biosciences’ rivals have higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Pulse Biosciences rivals beat Pulse Biosciences on 7 of the 10 factors compared.
Pulse Biosciences Company Profile
Pulse Biosciences, Inc., formerly Electroblate, Inc., is a development-stage medical device company using a platform technology called Nano-Pulse Electro-Signaling (NPES). NPES is a local and drug-free technology that utilizes nanosecond pulsed electric fields to induce cell signaling and the activation of cellular pathways in tissue. NPES provides treatment in a range of dermatology and aesthetic applications. It offers treatment for minimally invasive applications, such as cardiac ablation, lung disease, Barret’s esophagus, thyroid nodules, and ear, nose and throat (ENT) papillomas. The Company is developing a system for the delivery of NPES treatments, identified as the PulseTx system (PulseTx). The PulseTx system delivers NPES pulses through its tunable pulse generator and its planned suite of electrodes. The PulseTx system pulses are applied directly to tissue through electrodes, creating transient nanometer pores in cell and organelle membranes.
Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.